Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development.

Dumet C, Pottier J, Gouilleux-Gruart V, Watier H.

MAbs. 2019 Nov-Dec;11(8):1341-1350. doi: 10.1080/19420862.2019.1664365. Epub 2019 Sep 26. Erratum in: MAbs. 2019 Nov-Dec;11(8):1.

2.

Evolutionary Story of the Low/Medium-Affinity IgG Fc Receptor Gene Cluster.

Lejeune J, Brachet G, Watier H.

Front Immunol. 2019 Jun 6;10:1297. doi: 10.3389/fimmu.2019.01297. eCollection 2019.

3.

Targets for MAbs: innovative approaches for their discovery & validation, LabEx MAbImprove 6th antibody industrial symposium, June 25-26, 2018, Montpellier, France.

Martineau P, Watier H, Pèlegrin A, Turtoi A.

MAbs. 2019 Jul;11(5):812-825. doi: 10.1080/19420862.2019.1612691. Epub 2019 May 16.

4.

MAbTope: A Method for Improved Epitope Mapping.

Bourquard T, Musnier A, Puard V, Tahir S, Ayoub MA, Jullian Y, Boulo T, Gallay N, Watier H, Bruneau G, Reiter E, Crépieux P, Poupon A.

J Immunol. 2018 Nov 15;201(10):3096-3105. doi: 10.4049/jimmunol.1701722. Epub 2018 Oct 15.

5.

Rituximab mechanisms of action in B-CLL: a new piece of the puzzle.

Watier H.

Oncotarget. 2018 Aug 28;9(67):32732-32733. doi: 10.18632/oncotarget.26016. eCollection 2018 Aug 28. No abstract available.

6.

Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27-28, 2017, Tours, France.

Martin C, Kizlik-Masson C, Pèlegrin A, Watier H, Viaud-Massuard MC, Joubert N.

MAbs. 2018 Feb/Mar;10(2):210-221. doi: 10.1080/19420862.2017.1412130. Epub 2018 Jan 9.

7.

[Find your way in the jungle of mAbs].

Watier H.

Transfus Clin Biol. 2017 Sep;24(3):216-217. doi: 10.1016/j.tracli.2017.05.008. Epub 2017 Jun 12. Review. French.

PMID:
28619531
8.

Obinutuzumab: what is there to learn from clinical trials?

Cartron G, Watier H.

Blood. 2017 Aug 3;130(5):581-589. doi: 10.1182/blood-2017-03-771832. Epub 2017 Jun 5. Review.

PMID:
28584136
9.

Crucial Role for Immune Complexes but Not FcRn in Immunization against Anti-TNF-α Antibodies after a Single Injection in Mice.

Arnoult C, Brachet G, Cadena Castaneda D, Azzopardi N, Passot C, Desvignes C, Paintaud G, Heuzé-Vourc'h N, Watier H, Gouilleux-Gruart V.

J Immunol. 2017 Jul 15;199(2):418-424. doi: 10.4049/jimmunol.1601246. Epub 2017 Jun 5.

10.

Immunoassays for Measuring Serum Concentrations of Monoclonal Antibodies and Anti-biopharmaceutical Antibodies in Patients.

Darrouzain F, Bian S, Desvignes C, Bris C, Watier H, Paintaud G, de Vries A.

Ther Drug Monit. 2017 Aug;39(4):316-321. doi: 10.1097/FTD.0000000000000419. Review.

PMID:
28570370
11.

Contribution of physiologists to the identification of the humoral component of immunity in the 19th century.

Lahaie YM, Watier H.

MAbs. 2017 Jul;9(5):774-780. doi: 10.1080/19420862.2017.1325051. Epub 2017 May 30.

12.

Antibodies targeting G protein-coupled receptors: Recent advances and therapeutic challenges.

Ayoub MA, Crépieux P, Koglin M, Parmentier M, Pin JP, Poupon A, Reiter E, Smit M, Steyaert J, Watier H, Wilkinson T.

MAbs. 2017 Jul;9(5):735-741. doi: 10.1080/19420862.2017.1325052. Epub 2017 May 5.

13.

New structural formats of therapeutic antibodies for rheumatology.

Dumet C, Pottier J, Gouilleux V, Watier H.

Joint Bone Spine. 2018 Jan;85(1):47-52. doi: 10.1016/j.jbspin.2017.04.007. Epub 2017 Apr 28. Review.

PMID:
28461199
14.

MAbDelivery: Administration routes for antibody therapy Third LabEx MAbImprove industrial workshop, July 2, 2015 Tours, France.

Bodier-Montagutelli E, Respaud R, Watier H, Guillon-Munos A.

MAbs. 2017 May/Jun;9(4):579-585. doi: 10.1080/19420862.2017.1298899. Epub 2017 Feb 28.

15.

Theranostic of biopharmaceuticals.

Chaigne B, Watier H.

Pharmacol Ther. 2017 Jul;175:67-74. doi: 10.1016/j.pharmthera.2017.02.035. Epub 2017 Feb 14. Review.

PMID:
28223229
16.

Rethinking the INN system for therapeutic antibodies.

Pottier J, Chastang R, Dumet C, Watier H.

MAbs. 2017 Jan;9(1):5-11. doi: 10.1080/19420862.2016.1255520. Epub 2016 Nov 3.

17.

Repeated decrease of CD4+ T-cell counts in patients with rheumatoid arthritis over multiple cycles of rituximab treatment.

Lavielle M, Mulleman D, Goupille P, Bahuaud C, Sung HC, Watier H, Thibault G.

Arthritis Res Ther. 2016 Oct 28;18(1):253.

18.

Combined Metabolomics and Transcriptomics Approaches to Assess the IL-6 Blockade as a Therapeutic of ALS: Deleterious Alteration of Lipid Metabolism.

Patin F, Baranek T, Vourc'h P, Nadal-Desbarats L, Goossens JF, Marouillat S, Dessein AF, Descat A, Hounoum BM, Bruno C, Watier H, Si-Tahar M, Leman S, Lecron JC, Andres CR, Corcia P, Blasco H.

Neurotherapeutics. 2016 Oct;13(4):905-917. doi: 10.1007/s13311-016-0461-3.

19.

Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop.

Houot R, Gaulard P, Schreiber R, Mellman I, Lambotte O, Coulie PG, Fest T, Korman A, Levy R, Shipp M, Tarte K, Kohrt H, Marabelle A, Ansell S, Watier H, van Elsas A, Balakumaran A, Arce Vargas F, Quezada SA, Salles G, Olive D.

Oncoimmunology. 2016 May 19;5(7):e1186323. doi: 10.1080/2162402X.2016.1186323. eCollection 2016 Jul.

20.

Eculizumab epitope on complement C5: Progress towards a better understanding of the mechanism of action.

Brachet G, Bourquard T, Gallay N, Reiter E, Gouilleux-Gruart V, Poupon A, Watier H.

Mol Immunol. 2016 Sep;77:126-31. doi: 10.1016/j.molimm.2016.07.016. Epub 2016 Aug 5.

PMID:
27497837
21.

Inhibitors and Antibody Fragments as Potential Anti-Inflammatory Therapeutics Targeting Neutrophil Proteinase 3 in Human Disease.

Korkmaz B, Lesner A, Guarino C, Wysocka M, Kellenberger C, Watier H, Specks U, Gauthier F, Jenne DE.

Pharmacol Rev. 2016 Jul;68(3):603-30. doi: 10.1124/pr.115.012104. Review.

PMID:
27329045
22.

IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding.

Ternant D, Arnoult C, Pugnière M, Dhommée C, Drocourt D, Perouzel E, Passot C, Baroukh N, Mulleman D, Tiraby G, Watier H, Paintaud G, Gouilleux-Gruart V.

J Immunol. 2016 Jan 15;196(2):607-13. doi: 10.4049/jimmunol.1501780. Epub 2015 Dec 18.

23.

Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab.

Rollin J, Payancé A, Gouilleux-Gruart V, Boisdron-Celle M, Azzopardi N, Morel A, Gruel Y, Paintaud G, Gamelin E, Watier H, Lecomte T.

Pharmacogenomics. 2015 Dec;16(18):2035-43. doi: 10.2217/pgs.15.139. Epub 2015 Nov 30.

PMID:
26615857
24.

Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule.

Gatault P, Brachet G, Ternant D, Degenne D, Récipon G, Barbet C, Gyan E, Gouilleux-Gruart V, Bordes C, Farrell A, Halimi JM, Watier H.

MAbs. 2015;7(6):1205-11. doi: 10.1080/19420862.2015.1086049. Epub 2015 Sep 4.

25.

Monoclonal antibodies in excess: A simple way to avoid immunogenicity in patients?

Chaigne B, Watier H.

J Allergy Clin Immunol. 2015 Sep;136(3):814-6. doi: 10.1016/j.jaci.2015.03.013. Epub 2015 Apr 28. No abstract available.

PMID:
25930194
26.

Successful rapid desensitization to the antibody-drug conjugate brentuximab vedotin in a patient with refractory Hodgkin lymphoma.

Fizesan M, Boin C, Aujoulat O, Newinger G, Ghergus D, Watier H, Lustig H, Ojeda-Uribe M.

J Oncol Pharm Pract. 2016 Feb;22(1):188-92. doi: 10.1177/1078155214567164. Epub 2015 Jan 12. No abstract available.

PMID:
25586990
27.

Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis.

Ternant D, Ducourau E, Fuzibet P, Vignault C, Watier H, Lequerré T, Le Loët X, Vittecoq O, Goupille P, Mulleman D, Paintaud G.

Br J Clin Pharmacol. 2015 Feb;79(2):286-97. doi: 10.1111/bcp.12509.

28.

[Biotherapies, immunotherapies, targeted therapies, biopharmaceuticals… which word should be used?].

Watier H.

Med Sci (Paris). 2014 May;30(5):567-75. doi: 10.1051/medsci/20143005021. Epub 2014 Jun 13. French.

29.

Detection of antiranibizumab antibodies among patients with exudative age-related macular degeneration.

Leveziel N, Pelat T, Watier H, Thullier P, Souied EH.

Ophthalmologica. 2014;232(1):53-6. doi: 10.1159/000360186. Epub 2014 May 20.

PMID:
24854579
30.

MAbImprove: a French "Laboratoire d'excellence" (LabEx) dedicated to therapeutic antibodies.

Pèlegrin A, Daguet A, Watier H.

MAbs. 2014 Jul-Aug;6(4):803-4. doi: 10.4161/mabs.29262. Epub 2014 May 16. No abstract available.

31.

Unexplained abuses of human IgG subclass denomination in antibody patents.

Pottier J, Watier H.

BioDrugs. 2014 Aug;28(4):327-9. doi: 10.1007/s40259-014-0095-0. No abstract available.

PMID:
24756340
32.

Antibody biosimilars: fears or opportunities?: First LabEx MAbImprove industrial workshop, May 28, 2013; Tours, France.

Guillon-Munos A, Daguet A, Watier H.

MAbs. 2014 Jul-Aug;6(4):805-9. doi: 10.4161/mabs.28831. Epub 2014 Apr 8.

33.

Towards an individualised target concentration of adalimumab in rheumatoid arthritis.

Ducourau E, Ternant D, Lequerré T, Fuzibet P, Le Loët X, Watier H, Goupille P, Paintaud G, Vittecoq O, Mulleman D.

Ann Rheum Dis. 2014 Jul;73(7):1428-9. doi: 10.1136/annrheumdis-2013-204971. Epub 2014 Feb 18. No abstract available.

PMID:
24550169
34.

Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis.

Ternant D, Ducourau E, Perdriger A, Corondan A, Le Goff B, Devauchelle-Pensec V, Solau-Gervais E, Watier H, Goupille P, Paintaud G, Mulleman D.

Br J Clin Pharmacol. 2014 Jul;78(1):118-28. doi: 10.1111/bcp.12313.

35.

Influence of FcγRIIIA genetic polymorphism on T-lymphocyte depletion induced by rabbit antithymocyte globulins in kidney transplant patients.

Ternant D, Büchler M, Thibault G, Ohresser M, Watier H, Lebranchu Y, Paintaud G.

Pharmacogenet Genomics. 2014 Jan;24(1):26-34. doi: 10.1097/FPC.0000000000000017.

PMID:
24322002
36.

From Bretonneau to therapeutic antibodies, from specificity to specific remedies, Saint-Cyr-Sur-Loire, France, November 19, 2012.

Marchand C, Nouat R, Watier H.

MAbs. 2013 Sep-Oct;5(5):633-7. doi: 10.4161/mabs.25613. Epub 2013 Jul 8.

37.

Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response.

Mélet J, Mulleman D, Goupille P, Ribourtout B, Watier H, Thibault G.

Arthritis Rheum. 2013 Nov;65(11):2783-90. doi: 10.1002/art.38107.

38.

Therapeutic antibodies and infectious diseases, Tours, France, November 20-22, 2012.

Desoubeaux G, Daguet A, Watier H.

MAbs. 2013 Sep-Oct;5(5):626-32. doi: 10.4161/mabs.25300. Epub 2013 Jun 7.

39.

Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies.

Passot C, Azzopardi N, Renault S, Baroukh N, Arnoult C, Ohresser M, Boisdron-Celle M, Gamelin E, Watier H, Paintaud G, Gouilleux-Gruart V.

MAbs. 2013 Jul-Aug;5(4):614-9. doi: 10.4161/mabs.24815. Epub 2013 Apr 25.

40.

Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: correlations with clinical phenotype and polymorphism of the neonatal Fc receptor.

Gouilleux-Gruart V, Chapel H, Chevret S, Lucas M, Malphettes M, Fieschi C, Patel S, Boutboul D, Marson MN, Gérard L, Lee M, Watier H, Oksenhendler E; DEFI study group.

Clin Exp Immunol. 2013 Feb;171(2):186-94. doi: 10.1111/cei.12002.

41.

[Serotherapy, among therapeutic innovations and scientific progress in the late 19th and 20th centuries].

Daguet A, Watier H.

Rev Prat. 2012 Oct;62(8):1177-81. French. No abstract available.

PMID:
23227625
42.

FCGR2C genotyping by pyrosequencing reveals linkage disequilibrium with FCGR3A V158F and FCGR2A H131R polymorphisms in a Caucasian population.

Lejeune J, Piègu B, Gouilleux-Gruart V, Ohresser M, Watier H, Thibault G.

MAbs. 2012 Nov-Dec;4(6):784-7. doi: 10.4161/mabs.22287. Epub 2012 Oct 2.

43.

Should anti-TNF-α drug levels and/or anti-drug antibodies be assayed in patients treated for rheumatoid arthritis?

Mulleman D, Ducourau E, Paintaud G, Ternant D, Watier H, Goupille P.

Joint Bone Spine. 2012 Mar;79(2):109-12. doi: 10.1016/j.jbspin.2011.11.004. Epub 2012 Feb 20. No abstract available.

PMID:
22356754
44.

Fatal infusion reactions to cetuximab: role of immunoglobulin e-mediated anaphylaxis.

Pointreau Y, Commins SP, Calais G, Watier H, Platts-Mills TA.

J Clin Oncol. 2012 Jan 20;30(3):334; author reply 335. doi: 10.1200/JCO.2011.38.4701. Epub 2011 Dec 12. No abstract available.

45.

Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients.

Azzopardi N, Lecomte T, Ternant D, Boisdron-Celle M, Piller F, Morel A, Gouilleux-Gruart V, Vignault-Desvignes C, Watier H, Gamelin E, Paintaud G.

Clin Cancer Res. 2011 Oct 1;17(19):6329-37. doi: 10.1158/1078-0432.CCR-11-1081. Epub 2011 Sep 27.

46.

2nd Charles Richet et Jules Héricourt workshop: therapeutic antibodies and anaphylaxis; May 31-June 1, 2011, Tours, France.

Daguet A, Watier H.

MAbs. 2011 Sep-Oct;3(5):417-21. doi: 10.4161/mabs.3.5.17485. Epub 2011 Sep 1.

47.

Association of Fcγ receptor IIIA variant with a subset of anti-topoisomerase I-positive patients in systemic sclerosis: a descriptive pilot study.

Magnant J, Ohresser M, Allanore Y, de Monte M, Lafosse-Marin M, Degenne D, Guilmot JL, Watier H, Diot E.

Rheumatol Int. 2012 Jul;32(7):2203-7. doi: 10.1007/s00296-011-2026-4. Epub 2011 Jul 23.

PMID:
21785957
48.

Lability of IgE Levels Early in Life.

N'guessan K, Ternant D, Labarthe F, Watier H.

J Allergy (Cairo). 2011;2011:547389. doi: 10.1155/2011/547389. Epub 2011 Jun 20.

49.

Therapeutic drug monitoring of infliximab in spondyloarthritis: an observational open-label study.

Méric JC, Mulleman D, Ducourau E, Lauféron F, Miow Lin DC, Watier H, Goupille P, Paintaud G.

Ther Drug Monit. 2011 Aug;33(4):411-6. doi: 10.1097/FTD.0b013e318224f83d.

PMID:
21743380
50.

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases.

Ducourau E, Mulleman D, Paintaud G, Miow Lin DC, Lauféron F, Ternant D, Watier H, Goupille P.

Arthritis Res Ther. 2011 Jun 27;13(3):R105. doi: 10.1186/ar3386.

Supplemental Content

Loading ...
Support Center